BR112023018329A2 - Genoma de vetor lentiviral recombinante, plasmídeo de dna, partícula de vetor lentiviral recombinante, célula hospedeira, composição farmacêutica e método para a preparação de partículas de vetor lentiviral - Google Patents

Genoma de vetor lentiviral recombinante, plasmídeo de dna, partícula de vetor lentiviral recombinante, célula hospedeira, composição farmacêutica e método para a preparação de partículas de vetor lentiviral

Info

Publication number
BR112023018329A2
BR112023018329A2 BR112023018329A BR112023018329A BR112023018329A2 BR 112023018329 A2 BR112023018329 A2 BR 112023018329A2 BR 112023018329 A BR112023018329 A BR 112023018329A BR 112023018329 A BR112023018329 A BR 112023018329A BR 112023018329 A2 BR112023018329 A2 BR 112023018329A2
Authority
BR
Brazil
Prior art keywords
lentiviral vector
recombinant lentiviral
recombinant
host cell
pharmaceutical composition
Prior art date
Application number
BR112023018329A
Other languages
English (en)
Inventor
Catherine Blanc
Fanny Moncoq
François Anna
Jodie Lopez
Laleh Majlessi
Pierre Charneau
Original Assignee
Pasteur Institut
Theravectys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Theravectys filed Critical Pasteur Institut
Publication of BR112023018329A2 publication Critical patent/BR112023018329A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

genoma de vetor lentiviral recombinante, plasmídeo de dna, partícula de vetor lentiviral recombinante, célula hospedeira, composição farmacêutica e método para a preparação de partículas de vetor lentiviral. a invenção diz respeito a um genoma de vetor lentiviral recombinante compreendendo um polinucleotídeo que codifica um polipeptídeo de fusão, em que o referido polipeptídeo de fusão compreende, organizado da extremidade n-terminal para a c-terminal: um primeiro polipeptídeo compreendendo (i) uma cadeia invariante leve associada ao mhc-ii (ii); ou (ii) o domínio transmembrana do receptor de transferrina (tfr) e pelo menos um polipeptídeo antigênico de um patógeno. a invenção também diz respeito a um vetor lentiviral e composições farmacêuticas compreendendo o mesmo.
BR112023018329A 2021-03-12 2022-03-11 Genoma de vetor lentiviral recombinante, plasmídeo de dna, partícula de vetor lentiviral recombinante, célula hospedeira, composição farmacêutica e método para a preparação de partículas de vetor lentiviral BR112023018329A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21305317 2021-03-12
PCT/EP2022/056390 WO2022189656A1 (en) 2021-03-12 2022-03-11 Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host

Publications (1)

Publication Number Publication Date
BR112023018329A2 true BR112023018329A2 (pt) 2023-10-10

Family

ID=75426543

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018329A BR112023018329A2 (pt) 2021-03-12 2022-03-11 Genoma de vetor lentiviral recombinante, plasmídeo de dna, partícula de vetor lentiviral recombinante, célula hospedeira, composição farmacêutica e método para a preparação de partículas de vetor lentiviral

Country Status (8)

Country Link
EP (1) EP4305182A1 (pt)
JP (1) JP2024509976A (pt)
KR (1) KR20230156394A (pt)
CN (1) CN116981777A (pt)
AU (1) AU2022233021A1 (pt)
BR (1) BR112023018329A2 (pt)
CA (1) CA3209285A1 (pt)
WO (1) WO2022189656A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
EP2169073B1 (en) 1999-10-11 2013-11-13 Institut Pasteur Vector for the preparation of immunotherapeutical compositions
IL148900A0 (en) 1999-10-12 2002-09-12 Inst Nat Sante Rech Med Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
PT1957528E (pt) * 2005-11-30 2013-01-09 Univ Copenhagen Uma vacina de nucleótido
GB201321384D0 (en) * 2013-12-04 2014-01-15 Isis Innovation Molecular adjuvant

Also Published As

Publication number Publication date
CA3209285A1 (en) 2022-09-15
WO2022189656A1 (en) 2022-09-15
KR20230156394A (ko) 2023-11-14
CN116981777A (zh) 2023-10-31
EP4305182A1 (en) 2024-01-17
JP2024509976A (ja) 2024-03-05
AU2022233021A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
Wu et al. Evasion of antiviral immunity through sequestering of TBK1/IKKε/IRF3 into viral inclusion bodies
EP4272765A3 (en) Adeno-associated virus (aav) clade f vector and uses therefor
BR112018070637A2 (pt) receptores de células t
BR112018070600A2 (pt) receptores de células t
BR112015013183A2 (pt) proteínas de fusão para uso como aperfeiçoadores imunogênicos para indução de respostas de células t específicas para antígenos
BR112017003194A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, composição, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, vacina, vaso ou dispositivo de injeção, e, métodos para antagonizar lag3 em um paciente humano que necessita do mesmo, para tratamento de um câncer em um indivíduo para administrar o anticorpo, o fragmento, a composição, o polipeptídeo, a vacina, o vetor ou o polinucleotídeo de ligação ao antígeno a um indivíduo, para produção de um anticorpo ou de um fragmento de ligação ao antígeno do mesmo ou polipeptídeo e para detectar a presença de um peptídeo lag3 ou de um fragmento do mesmo em uma amostra.
BR112022014884A2 (pt) Vetor viral de vaccinia ankara modificado recombinante, vaccinia ankara modificado recombinante, e, método para reduzir ou prevenir uma infecção por coronavírus 2 da síndrome respiratória aguda grave
PE20121541A1 (es) Antigenos de virus de sincicio respiratorio recombinantes
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
BR112017001340A2 (pt) vacinas antidengue e anticorpos
BR112021026408A2 (pt) Receptores de célula t que reconhecem a mutação r175h ou y220c em p53
BR112022003241A2 (pt) Fontes de proteína não animal com propriedades fucionais
WO2021198706A3 (en) Coronavirus vaccines
BR112015014727B8 (pt) Composição imunogênica, vacina, e, uso de uma composição imunogênica
BR112016015678A2 (pt) Polipeptídeo contendo fragmentos mutantes de ospa, ácido nucleico, vetor, célula hospedeira, processo para sua produção, composição farmacêutica, e seu uso
BR112023018329A2 (pt) Genoma de vetor lentiviral recombinante, plasmídeo de dna, partícula de vetor lentiviral recombinante, célula hospedeira, composição farmacêutica e método para a preparação de partículas de vetor lentiviral
PH12019501320A1 (en) Effective vaccination against european strains of porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
BR112018001121A2 (pt) vetor recombinante do vírus orf (orfv), célula, composição, uso de um vetor recombinante de orfv, e, molécula de ácido nucleico
WO2018152375A3 (en) Engineered polypeptides
EA201890110A1 (ru) Рекомбинантные вирусные векторы, содержащие минорные белки prrsv, и способы их получения и применения
BR112023016617A2 (pt) Polipeptídeo, conjugado do polipeptídeo, vacina para a prevenção de infecção pelo vírus da imunodeficiência humana 1, vacina para o uso na prevenção de infecção pelo vírus da imunodeficiência humana 1, sequência de ácido desoxirribonucleico complementar, e, célula hospedeira
Lundu et al. Targeting of severe fever with thrombocytopenia syndrome virus structural proteins to the ERGIC (endoplasmic reticulum Golgi intermediate compartment) and Golgi complex
Lu et al. Spike gene deletion quasispecies in serum of patient with acute MERS‐CoV infection
Janaka et al. Retrovirus glycoprotein functionality requires proper alignment of the ectodomain and the membrane-proximal cytoplasmic tail
BR112018073669A2 (pt) proteína de fusão, composição de uma primeira proteína e uma segunda proteína, complexo de uma primeira proteína e uma segunda proteína, polinucleotídeos que codificam uma proteína de fusão, vetor contendo o polinucleotídeo, célula hospedeira contendo o polinucleotídeo, uso de uma proteína de fusão, composição farmacêutica, e composição farmacêutica para uso